Llwytho...
Treating acquired resistance to EGFR-tyrosine kinase inhibitors:still a work in progress
While most patients with metastatic non-small cell lung cancer (NSCLC) containing sensitizing mutations in the epidermal growth factor receptor (EGFR) gene will achieve an objective response to EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib or gefitinib, patients inevitably develop resista...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Transl Lung Cancer Res |
|---|---|
| Prif Awdur: | |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Pioneer Bioscience Publishing Company
2012
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4367570/ https://ncbi.nlm.nih.gov/pubmed/25806172 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2012.05.01 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|